CliffBio
small molecule

COBENFY

TROSPIUM CHLORIDE; XANOMELINE TARTRATE

Loss of exclusivityOctober 2039latest FDA-listed patent expiry
CompanyBristol-Myers Squibb →View the full company profile on CliffBio

Drug detail

Brand nameCOBENFY
Active ingredientTROSPIUM CHLORIDE; XANOMELINE TARTRATE
Strength20MG;EQ 100MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2024
Marketing statusRX

Listed patents

PatentExpiresType
12558317October 2039product
11471413September 2039use U-3513
11452692September 2039use U-3513
10933020September 2039product
11890378September 2039product
10925832September 2039product
10369143July 2030use U-3513
10265311July 2030use U-3513
10695339July 2030use U-3513
10238643July 2030product
10369144July 2030product

Regulatory exclusivity

CodeExpires
NCESeptember 2029

More from Bristol-Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

COBENFY patent cliff — loss of exclusivity October 2039 | CliffBio